Marsh & McLennan stock holds firm as investors eye October earnings and rising health costs

Marsh & McLennan stock (ISIN US5717481023) most recently closed at around 174.6 dollars on the New York Stock Exchange on September 17, 2026, giving the insurance brokerage and risk advisory group a market capitalization near 90.4 billion dollars at that level.

Earnings forecasts support Marsh & McLennan stock

Investor attention is now turning to Marsh & McLennan’s upcoming third-quarter 2026 earnings release, scheduled for October 15, 2026 before the market opens, with management set to host an investor call and webcast on the same day according to Ad-hoc-news.

Consensus estimates for Marsh & McLennan’s full-year 2026 performance point to solid growth in profitability, with the Zacks Consensus Estimate for 2026 earnings implying a 7.1 percent rise in earnings year over year and expectations for a further 9 percent increase in the following year, as reported by Ad-hoc-news.

Underlying revenue and margin outlook for 2026

Looking at the broader outlook, commentary from the company’s first-quarter 2026 earnings call indicates that Marsh & McLennan expects underlying revenue growth in 2026 to be similar to the levels achieved in 2025, alongside another year of margin expansion and solid adjusted earnings per share growth, according to Fortune.

Management also indicated that investors should expect more margin expansion in the second half of 2026 than in the first half, suggesting that profitability improvements could be weighted toward the upcoming quarters according to Fortune.

Health cost trends shape the risk advisory backdrop

For Marsh & McLennan’s consulting and risk advisory businesses, employer health cost dynamics are a key theme in 2026, with the company expecting an 11 percent increase in employer health costs before cost-control measures and a moderated 8.2 percent rise after planned benefit changes, according to Yahoo Finance.

This expected 8.2 percent post-mitigation increase in employer health costs for Marsh & McLennan’s client base compares with the steeper 11 percent rise before benefit adjustments, underscoring the importance of advisory work on benefit design and cost management highlighted by Yahoo Finance.

Stock level and upcoming earnings date

At the latest available close cited in recent trading commentary, Marsh & McLennan stock was quoted at around 174.6 dollars on the New York Stock Exchange on September 17, 2026, representing a modest decline of roughly 1.2 percent on the day and a position below the stock’s 200-day moving average near 177.9 dollars, with a market capitalization close to 90.4 billion dollars based on that price according to Ad-hoc-news.

More news and analyses on Marsh & McLennan stock